| EQS-News: Super Micro Computer, Inc.: Supermicro liefert den NVIDIA Vera Rubin NVL4 End-to-End-DCBBS-Blueprint mit nativer FP64-Leistung für konvergierte HPC- und KI-Infrastrukturen | EQS-News: Super Micro Computer, Inc.
/ Schlagwort(e): Produkteinführung
Supermicro liefert den NVIDIA Vera Rubin NVL4 End-to-End-DCBBS-Blueprint mit nativer FP64-Leistung für... ► Artikel lesen |
| Super Micro Computer springt an: Aktie jetzt zum Kauf empfohlen! | Die Anteile des KI-Server-Spezialisten starten schwungvoll in die neue Handelswoche, nachdem ein Analystenhaus den Kauf der Aktie empfohlen hat. KI-Server-Aktien heben ab, Super Micro Computer bleibt... ► Artikel lesen |
| Super Micro Computer, Inc.: Supermicro Delivers NVIDIA Vera Rubin NVL4 End-to-End DCBBS Blueprint with Native FP64 Performance for Converged HPC and AI Infrastructure | Total solution includes up to 1,152 NVIDIA Rubin GPUs and 576 NVIDIA Vera CPUs in liquid-cooled racks-3.2MW Scalable Unit delivers next-generation performance for AI workloads and FP64 simulation... ► Artikel lesen |
| XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen |
| Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen |
| CF Industries Holdings Inc. Reveals Advance In Q1 Bottom Line | WASHINGTON (dpa-AFX) - CF Industries Holdings Inc. (CF) reported a profit for its first quarter that Increased, from last yearThe company's bottom line totaled $615 million, or $3.98 per share.... ► Artikel lesen |
| Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen |
| Angelini Pharma; Catalyst Pharmaceuticals: Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease | The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration... ► Artikel lesen |
| Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Hetero Labs Ltd. | As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May... ► Artikel lesen |